Literature DB >> 17253502

Combined psychotherapy plus antidepressants for panic disorder with or without agoraphobia.

T A Furukawa1, N Watanabe, R Churchill.   

Abstract

BACKGROUND: Panic disorder can be treated with pharmacotherapy, psychotherapy or in combination, but the relative merits of combined therapy have not been well established.
OBJECTIVES: To review evidence concerning short- and long-term advantages and disadvantages of combined psychotherapy plus antidepressant treatment for panic disorder with or without agoraphobia, in comparison with either therapy alone. SEARCH STRATEGY: The Cochrane Collaboration Depression, Anxiety and Neurosis Controlled Trials Registers (CCDANCTR-Studies and CCDANCTR-References) were searched on 11/10/2005, together with a complementary search of the Cochrane Central Register of Controlled Trials and MEDLINE, using the keywords antidepressant and panic. A reference search, SciSearch and personal contact with experts were carried out. SELECTION CRITERIA: Two independent review authors identified randomised controlled trials comparing the combined therapy against either of the monotherapies among adult patients with panic disorder with or without agoraphobia. DATA COLLECTION AND ANALYSIS: Two independent review authors extracted data using predefined data formats, including study quality indicators. The primary outcome was relative risk (RR) of "response" i.e. substantial overall improvement from baseline as defined by the original investigators. Secondary outcomes included standardised weighted mean differences in global severity, panic attack frequency, phobic avoidance, general anxiety, depression and social functioning and relative risks of overall dropouts and dropouts due to side effects. MAIN
RESULTS: We identified 23 randomised comparisons (representing 21 trials, 1709 patients), 21 of which involved behaviour or cognitive-behaviour therapies. In the acute phase treatment, the combined therapy was superior to antidepressant pharmacotherapy (RR 1.24, 95% confidence interval (CI) 1.02 to 1.52) or psychotherapy (RR 1.17, 95% CI 1.05 to 1.31). The combined therapy produced more dropouts due to side effects than psychotherapy (number needed to harm (NNH) around 26). After the acute phase treatment, as long as the drug was continued, the superiority of the combination over either monotherapy appeared to persist. After termination of the acute phase and continuation treatment, the combined therapy was more effective than pharmacotherapy alone (RR 1.61, 95% CI 1.23 to 2.11) and was as effective as psychotherapy (RR 0.96, 95% CI 0.79 to 1.16). AUTHORS'
CONCLUSIONS: Either combined therapy or psychotherapy alone may be chosen as first line treatment for panic disorder with or without agoraphobia, depending on patient preference.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17253502      PMCID: PMC6823237          DOI: 10.1002/14651858.CD004364.pub2

Source DB:  PubMed          Journal:  Cochrane Database Syst Rev        ISSN: 1361-6137


  81 in total

1.  The managment of severe agoraphobia: a comparison of iproniazid and systematic desensitization.

Authors:  M S Lipsedge; J Hajioff; P Huggins; L Napier; J Pearce; D J Pike; M Rich
Journal:  Psychopharmacologia       Date:  1973-08-22

2.  Therapists, therapist variables, and cognitive-behavioral therapy outcome in a multicenter trial for panic disorder.

Authors:  J D Huppert; L F Bufka; D H Barlow; J M Gorman; M K Shear; S W Woods
Journal:  J Consult Clin Psychol       Date:  2001-10

3.  Duration of imipramine therapy and relapse in panic disorder with agoraphobia.

Authors:  Matig R Mavissakalian; James M Perel
Journal:  J Clin Psychopharmacol       Date:  2002-06       Impact factor: 3.153

4.  A prospective naturalistic study of 326 panic-agoraphobic patients treated with antidepressants.

Authors:  C Toni; G Perugi; F Frare; B Mata; B Vitale; F Mengali; M Recchia; G Serra; H S Akiskal
Journal:  Pharmacopsychiatry       Date:  2000-07       Impact factor: 5.788

5.  Imipramine in the treatment of agoraphobia: dose-response relationships.

Authors:  M Mavissakalian; J Perel
Journal:  Am J Psychiatry       Date:  1985-09       Impact factor: 18.112

6.  A meta-analysis of treatments for panic disorder.

Authors:  G A Clum; G A Clum; R Surls
Journal:  J Consult Clin Psychol       Date:  1993-04

7.  Bias in treatment assignment in controlled clinical trials.

Authors:  T C Chalmers; P Celano; H S Sacks; H Smith
Journal:  N Engl J Med       Date:  1983-12-01       Impact factor: 91.245

Review 8.  WCA recommendations for the long-term treatment of panic disorder.

Authors:  Mark H Pollack; Christer Allgulander; Borwin Bandelow; Giovanni B Cassano; John H Greist; Eric Hollander; David J Nutt; Ahmed Okasha; Richard P Swinson
Journal:  CNS Spectr       Date:  2003-08       Impact factor: 3.790

9.  Treatment of endogenous anxiety with phobic, hysterical, and hypochondriacal symptoms.

Authors:  D V Sheehan; J Ballenger; G Jacobsen
Journal:  Arch Gen Psychiatry       Date:  1980-01

10.  Differential treatment of phobias: use of imipramine for panic attacks.

Authors:  C M Zitrin
Journal:  J Behav Ther Exp Psychiatry       Date:  1983-03
View more
  28 in total

Review 1.  The modification of attentional bias to emotional information: A review of the techniques, mechanisms, and relevance to emotional disorders.

Authors:  Michael Browning; Emily A Holmes; Catherine J Harmer
Journal:  Cogn Affect Behav Neurosci       Date:  2010-03       Impact factor: 3.282

2.  Chest pain--consider panic disorder.

Authors:  Sam G Campbell; Allan A Abbass
Journal:  Can Fam Physician       Date:  2007-05       Impact factor: 3.275

3.  Combined antidepressants and CBT for panic disorder with agoraphobia.

Authors:  Nicholas J Coupland
Journal:  J Psychiatry Neurosci       Date:  2008-03       Impact factor: 6.186

Review 4.  [Guideline-oriented inpatient psychiatric psychotherapeutic/psychosomatic treatment of anxiety disorders : How many personnel are need?].

Authors:  B Bandelow; U Lueken; J Wolff; F Godemann; C Wolff-Menzler; J Deckert; A Ströhle; M Beutel; J Wiltink; K Domschke; M Berger
Journal:  Nervenarzt       Date:  2016-03       Impact factor: 1.214

Review 5.  Comparison of combined psycho- and pharmacotherapy with monotherapy in anxiety disorders: controversial viewpoints and clinical perspectives.

Authors:  P Zwanzger; J Diemer; B Jabs
Journal:  J Neural Transm (Vienna)       Date:  2008-09-23       Impact factor: 3.575

6.  The Efficacy of Cognitive Behavioral Therapy: A Review of Meta-analyses.

Authors:  Stefan G Hofmann; Anu Asnaani; Imke J J Vonk; Alice T Sawyer; Angela Fang
Journal:  Cognit Ther Res       Date:  2012-07-31

Review 7.  Panic disorder.

Authors:  Shailesh Kumar; Darren Malone
Journal:  BMJ Clin Evid       Date:  2008-12-16

8.  Internet-versus group-administered cognitive behaviour therapy for panic disorder in a psychiatric setting: a randomised trial.

Authors:  Jan Bergström; Gerhard Andersson; Brjánn Ljótsson; Christian Rück; Sergej Andréewitch; Andreas Karlsson; Per Carlbring; Erik Andersson; Nils Lindefors
Journal:  BMC Psychiatry       Date:  2010-07-02       Impact factor: 3.630

Review 9.  Canadian clinical practice guidelines for the management of anxiety, posttraumatic stress and obsessive-compulsive disorders.

Authors:  Martin A Katzman; Pierre Bleau; Pierre Blier; Pratap Chokka; Kevin Kjernisted; Michael Van Ameringen; Martin M Antony; Stéphane Bouchard; Alain Brunet; Martine Flament; Sophie Grigoriadis; Sandra Mendlowitz; Kieron O'Connor; Kiran Rabheru; Peggy M A Richter; Melisa Robichaud; John R Walker
Journal:  BMC Psychiatry       Date:  2014-07-02       Impact factor: 3.630

10.  Naturopathic care for anxiety: a randomized controlled trial ISRCTN78958974.

Authors:  Kieran Cooley; Orest Szczurko; Dan Perri; Edward J Mills; Bob Bernhardt; Qi Zhou; Dugald Seely
Journal:  PLoS One       Date:  2009-08-31       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.